X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GFB-024
Therapeutic Area: Nephrology Product Name: GFB-024
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
Details:
Goldfinch Bio observed that treatment with GFB-024 resulted in inhibition of CB1 receptor signaling, protecting against both podocyte and tubular cell injury, with negligible exposure in the brain and no central nervous system physiological effect.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GFB-887
Therapeutic Area: Nephrology Product Name: GFB-887
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Eventide Asset Management
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 30, 2020
Details:
Proceeds from the Series B financing will enable the advancement of GFB-887 and GFB-024 through three potential clinical proof-of-concept readouts and will also support continued development of the Company’s discovery platform and preclinical pipeline.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
